Idelalisib

ASCO '14 Preview: Blood Cancer Data from Pharmacyclics, Gilead, Abbvie
TheStreet.com
Thu, 05/15/14 - 08:29 am
ASCO
Gilead Sciences
AbbVie
Pharmacyclics
Imbruvica
CLL
Idelalisib
mantle cell lymphoma
ABT-199
6 Drugs That Could Move the Pharma Market
Wall St Cheat Sheet
Wed, 04/30/14 - 12:37 pm
Gilead Sciences
Teva Pharmaceuticals
Copaxone
Idelalisib
Bristol-Myers Squibb
nivolumab
Cyramza
Eli Lilly
Pfizer
palbociclib
Sovaldi
Standard Review for Gilead's Oncology Candidate
Yahoo/Zacks.com
Tue, 01/14/14 - 11:52 am
Gilead Sciences
Idelalisib
refractory indolent non-Hodgkins lymphoma
FDA Accepts New Drug Application for Gilead’s Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin’s Lymphoma
Yahoo
Mon, 01/13/14 - 09:41 am
FDA
Gilead Sciences
Idelalisib
refractory indolent non-Hodgkins lymphoma
Gilead’s Idelalisib Significantly Reduces Rate of Disease Progression or Death in Phase 3 Chronic Lymphocytic Leukemia Study
Yahoo
Mon, 11/18/13 - 10:28 am
Gilead
Idelalisib
CLL
chronic lymphocytic leukemia
Gilead Stops Leukemia Drug Trial Early on Patient Benefit
Bloomberg
Thu, 10/10/13 - 08:13 am
Gilead Sciences
Idelalisib
Rituxan
chronic lymphocytic leukemia
[video]3 Blood Cancer Drug Hopefuls in the Spotlight
Motley Fool
Thu, 06/20/13 - 07:46 am
Infinity Pharmaceuticals
JNJ
Pharmacyclics
Gilead
non-Hodgkin's lymphoma
ibrutinib
Idelalisib
IPI-145
Tackling Cancer: Leukemia's Biggest Current and Upcoming Players
Motley Fool
Mon, 05/20/13 - 11:40 am
leukemia
Sprycel
Bristol-Myers Squibb
Gleevec
Novartis
Iclusig
Ariad Pharmaceuticals
Bosulif
Pfizer
Erwinaze
Jazz Pharmaceuticals
Idelalisib
Gilead
ibrutinib
Pharmacyclics